Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (617)	4/2/1998 8:16:00 PM
From: edna lipiner	Read Replies (2) \| Respond to of 965

This news about CORR actually will boost CNTO in long run. Check out medical dudes on Yahoo board who explain why the uninformed jumped on CORR (clue: inferior product- more side effects). This whole thing (massive orgy of run-up for CORR) highlights how important market is for these drugs even if CNTO has to share some sales. With-in an hour CNTO recoverd 50% of the "shocking news". CORR is now adequately priced, investors now could return to CNTO which has a superior product and a few more tricks in the bag. No analyst cut their ratings. What's Merril Lynch going to do -cut CNTO back to 56 range? Stay on the roller coaster to 70.